Please ensure Javascript is enabled for purposes of website accessibility

Why Investors Didn't Like 10x Genomics' Q1 Results

By Keith Speights - May 6, 2021 at 6:04AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company delivered tremendous revenue growth but a deteriorating bottom line.

10x Genomics (TXG 3.67%) has been sizzling hot for much of 2021 so far. It hasn't hurt that Cathie Wood has been busy scooping up shares of the genomics company for her ARK Innovation ETF.

However, that sizzle seems likely to fizzle somewhat now. 10x Genomics announced its first-quarter results after the market closed Wednesday. The life sciences stock sank nearly 10% in after-hours trading. Here are the highlights from the company's Q1 update.

A DNA double helix with an image of a person's head and 1s and 0s in the background.

Image source: Getty Images.

By the numbers

10x Genomics reported revenue in the first quarter of $105.8 million, an impressive 47% year-over-year jump. This result topped the average analysts' estimate of $102.5 million.

The company announced a net loss of $11.6 million, or $0.11 per share, in the first quarter based on generally accepted accounting principles (GAAP). In the prior-year period, 10x posted a GAAP net loss of $21.1 million, or $0.22 per share. The consensus Wall Street estimate projected a Q1 net loss of $0.27 per share.

10x ended the first quarter with cash and cash equivalents of $617.2 million. This cash position was down slightly from the $663.6 million on hand as of Dec. 31, 2020.

Behind the numbers

10x Genomics CEO Serge Saxonov said, "We had a solid start to the year highlighted by strong growth across the business and the incredible response to the innovation revealed at our inaugural Xperience event." That strong growth was primarily due to higher consumables revenue.

This fits right into 10x's strategy. As the company builds the installed base for its genomic-sequencing instruments, consumables revenue will naturally increase.

10x's gross margin rose to 84% in the first quarter of 2021 from 79% in the prior-year period. This solid increase stemmed primarily from lower accrued royalties connected to an ongoing legal dispute.

Despite this higher gross margin, the company's bottom line deteriorated. The main culprit was significantly higher stock-based compensation expenses than in the prior-year period.

Looking ahead

10x Genomics maintained its full-year 2021 revenue guidance of between $480 million and $500 million. This range reflects year-over-year growth of between 61% and 67%. The midpoint of the range is a little short of the consensus Wall Street revenue estimate of $495 million.

However, the long-term prospects for 10x appear to be quite good. Saxonov said, "The 10x team is focused on product innovation and committed to delivering a great experience for our customers as we look to drive the Century of Biology."

Keith Speights has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends 10x Genomics Inc. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

10x Genomics, Inc. Stock Quote
10x Genomics, Inc.
TXG
$45.09 (3.67%) $1.59

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
379%
 
S&P 500 Returns
123%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/09/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.